Aviso: para depositar documentos, por favor, inicia sesión e identifícate con tu cuenta de correo institucional de la UCM con el botón MI CUENTA UCM. No emplees la opción AUTENTICACIÓN CON CONTRASEÑA
 

Structural basis of drugs that increase cardiac inward rectifier Kir2.1 currents

dc.contributor.authorGómez García, Ricardo
dc.contributor.authorCaballero Collado, Ricardo
dc.contributor.authorBarana Muñoz, Adriana
dc.contributor.authorAmorós García, Irene
dc.contributor.authorde Palm, Sue Haida
dc.contributor.authorMatamoros, Marcos
dc.contributor.authorNúñez, Mercedes
dc.contributor.authorPérez Hernández, Marta
dc.contributor.authorIriepa, Isabel
dc.contributor.authorTamargo Menéndez, Juan
dc.contributor.authorDelpón Mosquera, María Eva
dc.date.accessioned2024-01-10T08:48:54Z
dc.date.available2024-01-10T08:48:54Z
dc.date.issued2014-11-01
dc.description.abstractAims: We hypothesize that some drugs, besides flecainide, increase the inward rectifier current (IK1) generated by Kir2.1 homotetramers (IKir2.1) and thus, exhibit pro- and/or antiarrhythmic effects particularly at the ventricular level. To test this hypothesis, we analysed the effects of propafenone, atenolol, dronedarone, and timolol on Kir2.x channels. Methods and results: Currents were recorded with the patch-clamp technique using whole-cell, inside-out, and cell-attached configurations. Propafenone (0.1 nM-1 µM) did not modify either IK1 recorded in human right atrial myocytes or the current generated by homo- or heterotetramers of Kir2.2 and 2.3 channels recorded in transiently transfected Chinese hamster ovary cells. On the other hand, propafenone increased IKir2.1 (EC50 = 12.0 ± 3.0 nM) as a consequence of its interaction with Cys311, an effect which decreased inward rectification of the current. Propafenone significantly increased mean open time and opening frequency at all the voltages tested, resulting in a significant increase of the mean open probability of the channel. Timolol, which interacted with Cys311, was also able to increase IKir2.1. On the contrary, neither atenolol nor dronedarone modified IKir2.1. Molecular modelling of the Kir2.1-drugs interaction allowed identification of the pharmacophore of drugs that increase IKir2.1. Conclusions: Kir2.1 channels exhibit a binding site determined by Cys311 that is responsible for drug-induced IKir2.1 increase. Drug binding decreases channel affinity for polyamines and current rectification, and can be a mechanism of drug-induced pro- and antiarrhythmic effects not considered until now.
dc.description.departmentDepto. de Farmacología y Toxicología
dc.description.facultyFac. de Medicina
dc.description.refereedTRUE
dc.description.sponsorshipMinisterio de Ciencia e Innovación
dc.description.sponsorshipInstituto de Salud Carlos III
dc.description.sponsorshipCentro Nacional de Investigaciones Cardiovasculares
dc.description.sponsorshipComunidad de Madrid
dc.description.sponsorshipSociedad Española de Cardiología
dc.description.statuspub
dc.identifier.citationGómez R, Caballero R, Barana A, Amorós I, De Palm SH, Matamoros M, Núñez M, Pérez-Hernández M, Iriepa I, Tamargo J, Delpón E. Structural basis of drugs that increase cardiac inward rectifier Kir2.1 currents. Cardiovasc Res. 2014 Nov 1;104(2):337-46. doi: 10.1093/cvr/cvu203
dc.identifier.doi10.1093/cvr/cvu203
dc.identifier.essn1755-3245
dc.identifier.issn0008-6363
dc.identifier.officialurlhttps://academic.oup.com/cardiovascres/article/104/2/337/2931029?login=true
dc.identifier.relatedurlhttps://pubmed.ncbi.nlm.nih.gov/25205296/
dc.identifier.urihttps://hdl.handle.net/20.500.14352/92156
dc.issue.number104
dc.journal.titleCardiovascular Research
dc.language.isoeng
dc.page.final346
dc.page.initial337
dc.publisherEuropean Society of Cardiology
dc.relation.projectIDSAF2011- 30088
dc.relation.projectIDSAF2011-30112
dc.relation.projectIDRed HERACLES RD06/0009
dc.relation.projectIDRed Investigación Cardiovascular RD12/0042/0011
dc.relation.projectIDPI11/ 01030
dc.relation.projectIDCNIC-13
dc.relation.projectIDCNIC-08-2009
dc.relation.projectIDS2010/BMD2374
dc.rights.accessRightsopen access
dc.subject.cdu615.01/.03
dc.subject.keywordAtenolol
dc.subject.keywordDronedarone
dc.subject.keywordIK1
dc.subject.keywordInward rectifier channels
dc.subject.keywordPropafenone
dc.subject.ucmFarmacología (Medicina)
dc.subject.unesco3209 Farmacología
dc.titleStructural basis of drugs that increase cardiac inward rectifier Kir2.1 currents
dc.typejournal article
dc.type.hasVersionVoR
dspace.entity.typePublication
relation.isAuthorOfPublicationdf79fd2c-2e90-44d0-b3ac-76ff241e2fc5
relation.isAuthorOfPublication40b81dbc-a87f-4b7d-982a-db1ecdcdf07b
relation.isAuthorOfPublication22eeb834-bbe3-48f1-a140-d26c5bd0cdd6
relation.isAuthorOfPublication36742207-526a-45e6-b33e-e711e180a5f9
relation.isAuthorOfPublication.latestForDiscoverydf79fd2c-2e90-44d0-b3ac-76ff241e2fc5

Download

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
25-FA_Gómez_Cardiovasc-Res_2014.pdf
Size:
879.35 KB
Format:
Adobe Portable Document Format

Collections